You Are Entering
In A New World
Of Cancer Treatment
With a new technology conceived to solve a treatment resistance that drugs or immunotherapy haven’t solved for over a century
The Problem
90%
of the volume of a tumor
receives little or no drug at all
in systemic cancer treatment*
Drugs need blood vessels to distribute in a tumor. Unfortunately blood vessels and lymphatics are chaotic, malfuntioning or collapsed in a tumor.
Drugs, antibodies, nanocarrier, precision target medicine, and immune T-cells, whatever their efficacy, don’t swim and can’t distribute well in the tumor volume.
*Source: Soltani & Chen 2012
The Starpax Technology
( Part I )
The Starpax Technology ( Part I )
THE MAGNETODRONES™
The living Starpax Magnetodrones™ can swim in tumor without using blood vessels. They are injected directly into the tumor and transport anticancer agents on their surface.
They are sensitive to specific magnetic fields created by the
Starpax Polartrak and are aerotactic, meaning they search for low oxygen (hypoxic zones) where stem cells are located.
They die within 60 minutes after injection.
The Starpax Technology
( Part II )
The Starpax Technology ( Part II )
The Starpax Technology
( Part II )
THE POLARTRAK®
The trajectory of the Magnetodrones™ is controlled in three dimensions by the Starpax PolarTrak® . This device generates virtual monopole magnetic fields to keep the Magnetodrones™ trapped inside the tumor and force them to distribute with millimetric precision throughout the volume of the tumor while releasing the anticancer drug on their path.
The PolarTrak delivered in June 2022 at the Montreal Jewish General Hospital
One More Problem
The Side Effects
1%
of modern anticancer drug in systemic injection reaches the tumor while 99%* of this toxic agent continues to circulate in the whole patient’s body causing side effects.
The Starpax Technology is designed to inject 100% of the Magnetodrones directly into the tumor. The PolarTrak creates a magnetic sphere around the tumor to keep the Magnetodrones trapped inside the tumor preventing them from circulating in the bloodstream in order to substantially eliminate side effects.
*Source: Rosenblum, Joshi & Tao. NATURE Communications, April 2018
STARPAX RESULTS(preclinical studies analyzed by independent laboratories)
PRECLINICAL STUDIES ON HUMAN TUMORS GROWN IN ANIMALS
TESTED ON HCT 116 TUMOR, one of the most aggressive human tumors
100% REMISSION RATE
Based on Preclinical Studies
NO MEANINGFUL SIDE EFFECTS OBSERVED
Based on Preclinical Studies
50 TIMES MORE DRUG IN THE TUMOR
Dose calculation according to clinical trials protocol to be used, compared to traditional chemotherapy
800 TIMES FEWER TOXIC MOLECULES IN THE BODY
Dose calculation according to clinical trials protocol to be used, compared to traditional chemotherapy
The Starpax Technology is not yet approved for commercial use. Clinical trials on humans are planned to begin in 2024.
The Global Solid Tumors Annual Market Expected By 2029
$ 901 billion*
The Starpax Technology intends to address solid tumors and metastases with its 3 therapeutic benefits in one treatment: localized chemo, hypoxic zones treatment, systemic immunotherapy.
*Source: Data Bridge 2021
Make History. Help Save Lives.
The Starpax technology aims to not only treat cancer more effectively and eliminate side effects, but also to enable a smoother recovery process empowering patients to get back to living their normal lives and spending time with the people they love.
The Starpax technology opens a new era of cancer treatment. Be the first to be part of this revolution by investing in Starpax.
*1.9 MILLION NEW CANCER CASES ARE PROJECTED IN USA FOR 2024. IT COULD BE YOU OR SOMEONE YOU LOVE.
*American Cancer Society
Disclosure
All results, assertions, deductions, and technoscientific or medical forward-looking claims by Starpax in this document are based either on independent third-party preclinical work and analysis conducted at reputable Canadian first-tier research institutions, GLP-certified labs, clinical research organizations, and papers from the scientific literature, or by design intended use of the technology on humans.
Starpax Technology is currently an investigational product
and is not yet approved for commercial use. Clinical trials on humans are expected to begin in 2025.
The information contained herein is confidential and is provided for the exclusive use of the Recipient and may not be reproduced, provided, disclosed to others, or used for any other purpose without written authorization by Netshares Financial Services, LLC. (“Placement Agent”) and the Issuer, and upon request, must be returned to the Issuer or Company or Placement Agent. Netshares Financial Services, LLC, a Texas limited liability company, is a FINRA/SEC registered Broker-Dealer in connection with any transaction involving the Company pertaining to the matters contained herein.
This presentation is for informational and educational purposes only and is not intended to provide specific investment advice or recommendations. The information contained in this presentation should not be construed as an offer to buy or sell any securities or investment products. Investing in securities and other financial products involves risk, and the value of investments can fluctuate. Past performance is no guarantee of future results. Before making any investment decisions, investors should carefully consider their investment objectives, risk tolerance, and financial situation. All investments involve taking on risk. It’s important that you go into any investment in a company with a full understanding that you could lose some or all of your money.
The issuer has prepared this presentation, and the issuer is solely responsible for its content. The issuer is not registered as an investment advisor, broker-dealer, or financial professional with the SEC or FINRA. This presentation is not reviewed or approved by any regulatory authority. The information presented in this presentation is based on data and information that the issuer believes to be reliable. However, the issuer makes no representation or warranty, express or implied, as to the accuracy, completeness, or timeliness of any information presented in this presentation.
This presentation may contain forward-looking statements that involve risks and uncertainties. Actual results may differ materially from those projected in the forward-looking statements. The issuer does not undertake any obligation to update or revise any forward-looking statements.
This presentation may only be suitable for some investors, and investors should seek the advice of a qualified professional before making any investment decisions. The SEC website (www.sec.gov) and FINRA website (www.finra.org) provide valuable information for investors and can assist in determining the suitability of an investment.
By viewing this presentation, you acknowledge and agree that the issuer and its affiliates, directors, officers, employees, and agents shall have no liability whatsoever for any direct or indirect, special or consequential damages, losses, or expenses arising in connection with this presentation or any use or reliance on the information contained herein.